Oracle's impeccable results come at a high price.

Oracle surpassed estimates for the quarter, and lifted its guidance for fiscal 2027 revenue. During the quarter, Oracle ...

Oracle's Q3 earnings showed 15% HCM growth and 1,000-plus AI agents live in applications, but no word on the rumored layoffs.

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock tumbled 12% Wednesday morning after regulatory filings revealed that NVIDIA (NASDAQ:NVDA) had completely divested its stake in the ...

Oracle Corp's ORCL latest earnings results may signal a broader trend for ETF investors: demand for artificial intelligence ...

Ten years ago, Oracle (NYSE: ORCL) and Salesforce (NYSE: CRM) were both navigating a pivotal shift: legacy software companies ...

Oracle's OCI revenue is growing 66% YOY, outpacing AWS and Azure. Oracle is selling profitable business units and accumulating tens of billions in debt to fund the data center expansion needed to ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The expanded fund, disclosed in a filing with the US Securities and Exchange Commission following Oracle's quarterly earnings ...

Oracle posted earnings that topped Wall Street estimates and lifted its outlook, as strong AI demand drove its sales and ...